<DOC>
	<DOCNO>NCT00891332</DOCNO>
	<brief_summary>This multicenter study design evaluate response rate S-1 plus Leucovorin ( 1 week 1 week ) first -line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Study S-1 Plus LV Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically prove adenocarcinoma Unresectable recurrent colorectal cancer Age20 â‰¤ enrollment Performance status 0 1 ( ECOG ) No prior treatment ( ex . radiation therapy , chemotherapy , hormonal therapy ) advance disease . Patients receive adjuvant chemotherapy 180 day enrollment allow receive S1 contain treatment shall exclude Adequate hematologic , hepatic renal function At least one measurable lesion RECIST criterion Serious drug hypersensitivity Pregnant nursing Bleeding gastrointestinal tract Diarrhea Simultaneously active double cancer Serious illness medical condition Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>